TY - JOUR
T1 - Association between C-reactive protein and risk of overall and 18 site-specific cancers in a Japanese case-cohort
AU - For the Japan Public Health Center-based Prospective Study Group
AU - Suzuki, Shiori
AU - Katagiri, Ryoko
AU - Yamaji, Taiki
AU - Sawada, Norie
AU - Imatoh, Takuya
AU - Ihira, Hikaru
AU - Inoue, Manami
AU - Tsugane, Shoichiro
AU - Iwasaki, Motoki
AU - Sawada, N.
AU - Tsugane, S.
AU - Iwasaki, M.
AU - Inoue, M.
AU - Yamaji, T.
AU - Katagiri, R.
AU - Miyamoto, Y.
AU - Ihira, H.
AU - Abe, S. K.
AU - Tanaka, S.
AU - Moriya, T.
AU - Minamizono, T.
AU - Shirai, Y.
AU - Kuniyoshi, H.
AU - Yoshimi, T.
AU - Sonoda, H.
AU - Tagami, T.
AU - Ando, T.
AU - Kimura, T.
AU - Kokubo, Y.
AU - Yamagishi, K.
AU - Mizoue, T.
AU - Nakamura, K.
AU - Takachi, R.
AU - Ishihara, J.
AU - Iso, H.
AU - Kitamura, T.
AU - Saito, I.
AU - Yasuda, N.
AU - Mimura, M.
AU - Sakata, K.
AU - Noda, M.
AU - Goto, A.
AU - Yatsuya, H.
N1 - Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2022/6/1
Y1 - 2022/6/1
N2 - Background: Evidence of the association between chronic low-grade inflammation, as reflected by C-reactive protein (CRP) measurements, and cancer risk is equivocal. Specifically, few studies have examined this in uncommon cancers and Asian populations. Methods: We utilised a case-cohort design consisting of multi-types of cancer (N = 3608), and a random subcohort (N = 4432) in a Japanese large population-based study, with a median follow-up time of 15.6 years, and measured baseline plasma CRP using high sensitivity assay. The hazard ratios (HRs) were estimated using weighted Cox proportional hazards methods. Results: The multivariable-adjusted HR (95% confidence interval) for the top quartile of CRP was 1.28 (1.11‒1.48) (Ptrend < 0.001) for overall cancer compared to the bottom quartile of CRP. Among site-specific cancers, higher CRP levels were associated with an increased risk of colorectal, lung, breast, biliary tract, and kidney cancer, and leukaemia. These positive associations remained among participants after >3 years’ follow-up. Furthermore, subgroup analyses for overall cancer robustly showed a positive association with CRP levels, regardless of sex and obesity. Conclusion: Our consistent findings suggested that chronic low-grade inflammation measured by CRP is associated with the risk of cancer.
AB - Background: Evidence of the association between chronic low-grade inflammation, as reflected by C-reactive protein (CRP) measurements, and cancer risk is equivocal. Specifically, few studies have examined this in uncommon cancers and Asian populations. Methods: We utilised a case-cohort design consisting of multi-types of cancer (N = 3608), and a random subcohort (N = 4432) in a Japanese large population-based study, with a median follow-up time of 15.6 years, and measured baseline plasma CRP using high sensitivity assay. The hazard ratios (HRs) were estimated using weighted Cox proportional hazards methods. Results: The multivariable-adjusted HR (95% confidence interval) for the top quartile of CRP was 1.28 (1.11‒1.48) (Ptrend < 0.001) for overall cancer compared to the bottom quartile of CRP. Among site-specific cancers, higher CRP levels were associated with an increased risk of colorectal, lung, breast, biliary tract, and kidney cancer, and leukaemia. These positive associations remained among participants after >3 years’ follow-up. Furthermore, subgroup analyses for overall cancer robustly showed a positive association with CRP levels, regardless of sex and obesity. Conclusion: Our consistent findings suggested that chronic low-grade inflammation measured by CRP is associated with the risk of cancer.
UR - http://www.scopus.com/inward/record.url?scp=85124338388&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124338388&partnerID=8YFLogxK
U2 - 10.1038/s41416-022-01715-8
DO - 10.1038/s41416-022-01715-8
M3 - Article
C2 - 35140343
AN - SCOPUS:85124338388
SN - 0007-0920
VL - 126
SP - 1481
EP - 1489
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 10
ER -